CNTB
NASDAQConnect Biopharma Holdings Limited
Price$1.93-0.14 (-6.78%)
01:30 PM07:45 PM
News · 26 weeks36-57%
2025-12-282026-06-21
Mix2290d
- SEC Filings7(32%)
- Other7(32%)
- Insider4(18%)
- Earnings2(9%)
- Analyst2(9%)
Latest news
25 items- PRConnect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway into 2H 2027 – SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study evaluating the safety and efficacy of rademikibart, the Company's next-generation, potentially best-in-class anti-interle
- INSIDERDirector Huang James bought $371,610 worth of Ordinary Shares (150,000 units at $2.48) (SEC Form 4)4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)
- SECSEC Form EFFECT filed by Connect Biopharma Holdings LimitedEFFECT - Connect Biopharma Holdings Ltd (0001835268) (Filer)
- ANALYSTCanaccord Genuity initiated coverage on Connect Biopharma with a new price targetCanaccord Genuity initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $6.00
- ANALYSTCantor Fitzgerald initiated coverage on Connect Biopharma with a new price targetCantor Fitzgerald initiated coverage of Connect Biopharma with a rating of Overweight and set a new price target of $4.00
- SECSEC Form F-3 filed by Connect Biopharma Holdings LimitedF-3 - Connect Biopharma Holdings Ltd (0001835268) (Filer)
- PRConnect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor ConferenceSAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at 9:30 a.m. ET. The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference. About
- SECSEC Form 10-Q filed by Connect Biopharma Holdings Limited10-Q - Connect Biopharma Holdings Ltd (0001835268) (Filer)
- SECConnect Biopharma Holdings Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)
- PRConnect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis – – Expect to report topline data from both Phase 2 Seabreeze STAT studies mid-2026 – – $20.2 million private placement financing closed on March 31, 2026 – SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three months ended March 31, 2026, and provided a business update. "W
- SECConnect Biopharma Holdings Limited filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)
- PRConnect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim AnalysisSAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the independent Data Monitoring Committee (DMC) overseeing its Phase 2 Seabreeze STAT asthma and COPD trials evaluating rademikibart, the Company's next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, has completed its review of the pre-specified interim analysis of efficacy with no recommendation for change in the sample size. "Based on the DMC's review of interim efficacy
- INSIDERSEC Form 4 filed by Xanthopoulos Kleanthis Gabriel4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)
- INSIDERSEC Form 4 filed by Liu Jean I4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)
- INSIDERSEC Form 4 filed by Huang James4 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)
- SECSEC Form 10-K filed by Connect Biopharma Holdings Limited10-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)
- SECConnect Biopharma Holdings Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)
- PRConnect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session at AAD – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies mid-2026 – – Entered into a securities purchase agreement for $20.2 million equity financing extending our cash runway into second half of 2027 – SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceuti
- PRConnect Biopharma Announces $20.2 Million Private Placement FinancingFunding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma," "Connect" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 6,130,000 shares of its ordinary shares in a private placement at a price of $3.25 per share with respect to any purchaser that is not owned or controlled by an individual who is an officer, dir
- PRRademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to placebo – – Data presented during late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting – – Company to host conference call and webcast today, March 30, 2026 at 8:00 a.m. ET – SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today anno
- PRConnect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV1 with many patients experiencing improvements in airway function of ≥200 mL as early as 15 minutes post-dosing – – The rapid improvement in FEV1 demonstrated with IV rademikibart in this study provides clinical confirmation of preclinical observations that rademikibart has a unique beneficial effect on bronchodilation – – Mean FEV1 improvements of ~200 - 400 mL were maintained through Day 29 in asthma and COPD patients – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD;
- SECConnect Biopharma Holdings Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)
- INSIDERSEC Form 3 filed by new insider Huang James3 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)
- INSIDERNew insider Szekeres David Leslie claimed ownership of 215,739 units of Ordinary Shares (SEC Form 3)3 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)
- INSIDERNew insider Quart Barry D claimed ownership of 224,034 units of Ordinary Shares (SEC Form 3)3 - Connect Biopharma Holdings Ltd (0001835268) (Issuer)
CNTB FAQ
7 questionsWhat does Connect Biopharma Holdings Limited do?
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell...Where does CNTB stock trade?
Connect Biopharma Holdings Limited (CNTB) is listed on NASDAQ.What sector and industry is CNTB in?
Connect Biopharma Holdings Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Connect Biopharma Holdings Limited go public?
Connect Biopharma Holdings Limited (CNTB) completed its IPO in 2021.What are analysts saying about CNTB?
Connect Biopharma Holdings Limited has had 6 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $600.00 price target on 2026-05-26. Recent price targets range from $400.00 to $1000.00.What companies are similar to CNTB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CNTB side-by-side with any of them on Quantisnow.How can I track CNTB on Quantisnow?
Quantisnow aggregates Connect Biopharma Holdings Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CNTB to receive live email and push alerts on every new disclosure.